Payment overview · 2025
General Payments
$58.56
2 reported records · 2 companies
Healthcare provider profile · identity verified
Larry E Smith, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VALDOSTA, GA · NPI 1548297195
Verified facts
What the public records show
CMS Open Payments records show Larry E Smith, M.D. received $58.56 in general payments during 2025 across 2 reported records.
Octapharma USA, Inc. accounted for 50.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $29.71 | 50.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.85 | 49.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $58.56 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CUTAQUIG Normalized: cutaquig |
Biological | Octapharma USA, Inc. | $29.71 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1322 | 231 |
| Amlodipine Besylate | Amlodipine Besylate | 951 | 143 |
| Pantoprazole Sodium | Pantoprazole Sodium | 675 | 142 |
| Potassium Chloride | Potassium Chloride | 665 | 87 |
| Mirtazapine | Mirtazapine | 630 | 60 |
| Quetiapine Fumarate | Quetiapine Fumarate | 572 | 47 |
| Gabapentin | Gabapentin | 571 | 73 |
| Valsartan | Valsartan | 565 | 46 |
| Omeprazole | Omeprazole | 534 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 517 | 93 |
| Metformin Hcl | Metformin Hcl | 508 | 74 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 499 | 138 |
| Carvedilol | Carvedilol | 491 | 64 |
| Eliquis | Apixaban | 460 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 449 | 34 |
| Donepezil Hcl | Donepezil Hcl | 446 | 28 |
| Furosemide | Furosemide | 444 | 57 |
| Hydralazine Hcl | Hydralazine Hcl | 431 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 428 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 398 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 365 | 50 |
| Sertraline Hcl | Sertraline Hcl | 349 | 47 |
| Allopurinol | Allopurinol | 344 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 314 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 305 | 52 |
| Glimepiride | Glimepiride | 304 | 47 |
| Famotidine | Famotidine | 293 | 24 |
| Lisinopril | Lisinopril | 289 | 61 |
| Felodipine Er | Felodipine | 287 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 280 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 272 | 73 |
| Jardiance | Empagliflozin | 253 | 33 |
| Prednisone | Prednisone | 214 | 105 |
| Fluticasone Propionate | Fluticasone Propionate | 192 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 12 |
| Pregabalin | Pregabalin | 185 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 182 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 181 | 24 |
| Finasteride | Finasteride | 175 | 23 |
| Trazodone Hcl | Trazodone Hcl | 165 | 32 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 163 | 32 |
| Temazepam | Temazepam | 160 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 150 | 40 |
| Metformin Hcl Er | Metformin Hcl | 144 | 32 |
| Levetiracetam | Levetiracetam | 140 | 15 |
| Memantine Hcl | Memantine Hcl | 138 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 134 | 14 |
| Azithromycin | Azithromycin | 125 | 92 |
| Spironolactone | Spironolactone | 122 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 120 | 57 |
| Clonidine Hcl | Clonidine Hcl | 119 | 13 |
| Tradjenta | Linagliptin | 116 | suppressed |
| Topiramate | Topiramate | 114 | 28 |
| Ondansetron Odt | Ondansetron | 112 | 39 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 111 | 34 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 109 | 24 |
| Losartan Potassium | Losartan Potassium | 109 | 25 |
| Naproxen | Naproxen | 109 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 104 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 100 | 68 |
| Meloxicam | Meloxicam | 100 | 19 |
| Bumetanide | Bumetanide | 97 | 11 |
| Colchicine | Colchicine | 95 | 22 |
| Januvia | Sitagliptin Phosphate | 92 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 88 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 16 |
| Lubiprostone | Lubiprostone | 82 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | suppressed |
| Primidone | Primidone | 79 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 77 | suppressed |
| Nifedipine Er | Nifedipine | 77 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 72 | 14 |
| Myrbetriq | Mirabegron | 69 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 68 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 11 |
| Tramadol Hcl | Tramadol Hcl | 67 | 15 |
| Lactulose | Lactulose | 66 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 12 |
| Alendronate Sodium | Alendronate Sodium | 62 | 14 |
| Methenamine Hippurate | Methenamine Hippurate | 62 | suppressed |
| Simvastatin | Simvastatin | 62 | suppressed |
| Mounjaro | Tirzepatide | 61 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 59 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 58 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | suppressed |
| Ozempic | Semaglutide | 55 | 13 |
| Telmisartan | Telmisartan | 54 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 13 |
| Sucralfate | Sucralfate | 53 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 52 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 52 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 52 | suppressed |
| Carbamazepine | Carbamazepine | 51 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 51 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 50 | suppressed |
| Olanzapine | Olanzapine | 50 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 50 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 50 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 48 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 46 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 12 |
| Fluconazole | Fluconazole | 39 | 17 |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 17 |
| Minoxidil | Minoxidil | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 33 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 33 | suppressed |
| Dutasteride | Dutasteride | 32 | suppressed |
| Nystatin | Nystatin | 32 | suppressed |
| Levemir Flexpen | Insulin Detemir | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 15 |
| Varenicline Tartrate | Varenicline Tartrate | 31 | 11 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 14 |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 28 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 28 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 27 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | 11 |
| Alprazolam | Alprazolam | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 18 |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 21 | suppressed |
| Invokana | Canagliflozin | 21 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | 11 |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Levemir | Insulin Detemir | 19 | suppressed |
| Levetiracetam Er | Levetiracetam | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 17 |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Constulose | Lactulose | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Novolog | Insulin Aspart | 17 | suppressed |
| Nyamyc | Nystatin | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | 12 |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 12 |
| Febuxostat | Febuxostat | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Paricalcitol | Paricalcitol | 12 | suppressed |
| Procrit | Epoetin Alfa | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 11 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $58.56 · 2 records | Octapharma USA, Inc. | CUTAQUIG, Ozempic | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error